The present invention discloses a hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by formulas I-a to I-d:

##STR00001##

The hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino prepared in the present invention has a maximum absorption wavelength of 600-650 nm and a molar extinction coefficient reaching about 20000-40000 M.sup.−1cm.sup.−1. Compared with unmodified hypocrellin or hypocrellin having only a 2-position modified, an absorption spectrum of the derivative is significantly red-shifted and the molar extinction coefficient is greatly improved, and the derivative can efficiently produce reactive oxygen species such as singlet oxygen in a photosensitive condition. In the same condition, the hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino involved in the present invention, when used as a photosensitizer, has a stronger ability to photo-dynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.

##STR00001##

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

The present disclosure discloses an expectorant compound, and specifically discloses compounds represented by formula I and formula II, pharmaceutically acceptable salts or tautomers thereof.

The present disclosure discloses an expectorant compound, and specifically discloses compounds represented by formula I and formula II, pharmaceutically acceptable salts or tautomers thereof.

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.

A novel compound for a capping layer, and an organic light-emitting device containing the same are disclosed.